149 related articles for article (PubMed ID: 27370710)
1. Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine.
Duley JA; Henman MG; Carpenter KH; Bamshad MJ; Marshall GA; Ooi CY; Wilcken B; Pinner JR
Mol Genet Metab; 2016 Sep; 119(1-2):83-90. PubMed ID: 27370710
[TBL] [Abstract][Full Text] [Related]
2. Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH.
Rainger J; Bengani H; Campbell L; Anderson E; Sokhi K; Lam W; Riess A; Ansari M; Smithson S; Lees M; Mercer C; McKenzie K; Lengfeld T; Gener Querol B; Branney P; McKay S; Morrison H; Medina B; Robertson M; Kohlhase J; Gordon C; Kirk J; Wieczorek D; Fitzpatrick DR
Hum Mol Genet; 2012 Sep; 21(18):3969-83. PubMed ID: 22692683
[TBL] [Abstract][Full Text] [Related]
3. Miller syndrome with novel dihydroorotate dehydrogenase gene mutations.
Kinoshita F; Kondoh T; Komori K; Matsui T; Harada N; Yanai A; Fukuda M; Morifuji K; Matsumoto T
Pediatr Int; 2011 Aug; 53(4):587-91. PubMed ID: 21851494
[No Abstract] [Full Text] [Related]
4. Protein instability and functional defects caused by mutations of dihydro-orotate dehydrogenase in Miller syndrome patients.
Fang J; Uchiumi T; Yagi M; Matsumoto S; Amamoto R; Saito T; Takazaki S; Kanki T; Yamaza H; Nonaka K; Kang D
Biosci Rep; 2012 Dec; 32(6):631-9. PubMed ID: 22967083
[TBL] [Abstract][Full Text] [Related]
5. Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction.
Fang J; Uchiumi T; Yagi M; Matsumoto S; Amamoto R; Takazaki S; Yamaza H; Nonaka K; Kang D
Biosci Rep; 2013 Feb; 33(2):e00021. PubMed ID: 23216091
[TBL] [Abstract][Full Text] [Related]
6. Dihydroorotate dehydrogenase depletion hampers mitochondrial function and osteogenic differentiation in osteoblasts.
Fang J; Yamaza H; Uchiumi T; Hoshino Y; Masuda K; Hirofuji Y; Wagener FA; Kang D; Nonaka K
Eur J Oral Sci; 2016 Jun; 124(3):241-5. PubMed ID: 27086500
[TBL] [Abstract][Full Text] [Related]
7. Insights into the mechanism of oxidation of dihydroorotate to orotate catalysed by human class 2 dihydroorotate dehydrogenase: a QM/MM free energy study.
Alves CN; Silva JR; Roitberg AE
Phys Chem Chem Phys; 2015 Jul; 17(27):17790-6. PubMed ID: 26087682
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of flavin reduction in class 2 dihydroorotate dehydrogenases.
Fagan RL; Nelson MN; Pagano PM; Palfey BA
Biochemistry; 2006 Dec; 45(50):14926-32. PubMed ID: 17154530
[TBL] [Abstract][Full Text] [Related]
10. Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis.
Björnberg O; Rowland P; Larsen S; Jensen KF
Biochemistry; 1997 Dec; 36(51):16197-205. PubMed ID: 9405053
[TBL] [Abstract][Full Text] [Related]
11. Extra phenotypic features in a girl with Miller syndrome.
Al Kaissi A; Roetzer KM; Ulz P; Heitzer E; Klaushofer K; Grill F
Clin Dysmorphol; 2011 Apr; 20(2):66-72. PubMed ID: 21346561
[TBL] [Abstract][Full Text] [Related]
12. Roles in binding and chemistry for conserved active site residues in the class 2 dihydroorotate dehydrogenase from Escherichia coli.
Fagan RL; Palfey BA
Biochemistry; 2009 Aug; 48(30):7169-78. PubMed ID: 19530672
[TBL] [Abstract][Full Text] [Related]
13. Finding disease variants in Mendelian disorders by using sequence data: methods and applications.
Ionita-Laza I; Makarov V; Yoon S; Raby B; Buxbaum J; Nicolae DL; Lin X
Am J Hum Genet; 2011 Dec; 89(6):701-12. PubMed ID: 22137099
[TBL] [Abstract][Full Text] [Related]
14. Familial postaxial acrofacial dysostosis syndrome.
Giannotti A; Digilio MC; Virgili Q; Obregon MG; Guadagni AM; Ventura T; Dallapiccola B
J Med Genet; 1992 Oct; 29(10):752. PubMed ID: 1433242
[No Abstract] [Full Text] [Related]
15. Protein production, kinetic and biophysical characterization of three human dihydroorotate dehydrogenase mutants associated with Miller syndrome.
Orozco Rodriguez JM; Krupinska E; Wacklin-Knecht H; Knecht W
Nucleosides Nucleotides Nucleic Acids; 2022; 41(12):1318-1336. PubMed ID: 35094635
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of flavin reduction in the class 1A dihydroorotate dehydrogenase from Lactococcus lactis.
Fagan RL; Jensen KF; Björnberg O; Palfey BA
Biochemistry; 2007 Apr; 46(13):4028-36. PubMed ID: 17341096
[TBL] [Abstract][Full Text] [Related]
17. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
18. Orotate (orotic acid): An essential and versatile molecule.
Löffler M; Carrey EA; Zameitat E
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):566-577. PubMed ID: 27906623
[TBL] [Abstract][Full Text] [Related]
19. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
20. Facial dysostoses: Etiology, pathogenesis and management.
Trainor PA; Andrews BT
Am J Med Genet C Semin Med Genet; 2013 Nov; 163C(4):283-94. PubMed ID: 24123981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
